Amylin Pharmaceuticals Annual Meeting

Presentation to Stockholders

May 24, 2001 - 10:00am

San Diego, CA

Click here to start


Table of Contents

Amylin Pharmaceuticals, Inc.

Agenda

Amylin Pharmaceuticals, Inc.

Safe Harbor Statement

Current Pipeline Status

Amylin Goals for 2001 SYMLIN™ (pramlintide acetate)

Amylin Goals for 2001 AC2993 and AC2993 LAR

Amylin Goals for 2001 AC3056 and Research

SYMLIN™ (pramlintide acetate) Overview

SYMLIN Patient Focus People With Diabetes Who Use Insulin

SYMLIN Market Opportunity United States

SYMLIN Market Opportunity: US Insulin Prescriptions Highly Concentrated

SYMLIN Commercial Operations Sales Planning Model

SYMLIN Commercial Operations Experienced Core Commercial Team

Amylin the Hormone Campaign

Amylin the Hormone Campaign

Upcoming Medical Meetings

AC2993 (synthetic exendin-4) Overview

AC2993 (synthetic exendin-4) Patient Focus

AC2993 (synthetic exendin-4) Potential Markets

AC2993 (synthetic exendin-4)

AC2993 (synthetic exendin-4)

AC2993 LAR

AC3056

Expanding the Pipeline

Financial Overview

2001 Corporate Presentations

Goals for 2001